论文部分内容阅读
目的通过尿激酶+肝素+华法令与单纯尿激酶+肝素治疗肺栓塞的对照分析研究,探讨尿激酶+肝素+华法令治疗肺栓塞的临床效果。方法 56例肺栓塞患者随机分成尿激酶+肝素+华法令治疗的治疗组,单纯尿激酶+肝素治疗的对照组,通过临床症状、疗效判断标准,比较两种方法治疗肺栓塞的临床效果。结果观察组治疗后患者呼吸困难、胸痛、咳嗽等不适与对照组比较有统计学差异(P<0.05)。临床疗效比较,治疗组明显优于对照组(P<0.01)。结论尿激酶+肝素+华法令以溶栓加抗凝疗联合治疗肺栓塞是及时且具有较高疗效的治疗方案。
Objective To investigate the clinical effect of urokinase + heparin + warfarin in the treatment of pulmonary embolism by urokinase + heparin + warfarin combined with urokinase + heparin alone. Methods Fifty-six patients with pulmonary embolism were randomly divided into treatment group treated with urokinase + heparin + warfarin and control group treated with urokinase + heparin alone. Clinical criteria and curative effect criteria were compared. The clinical efficacy of the two methods in treating pulmonary embolism was compared. Results The observation group patients with dyspnea after treatment, chest pain, cough and other discomfort compared with the control group were statistically significant (P <0.05). Compared with the clinical efficacy, the treatment group was significantly better than the control group (P <0.01). Conclusion Urokinase + heparin + warfarin combined with thrombolytic therapy and anticoagulant therapy for pulmonary embolism is a timely and highly effective treatment.